- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05149365
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation
Sitagliptin Efficacy and Safety for Prevention of Acute Graft Versus Host Disease in Patients Receiving Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective:
It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related haploid or unrelated donor ) allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and receiving standard GVHD prophylaxis.
Secondary Objectives
The following descriptive secondary objectives will be studied:
- Determine the tolerability and potential toxicity of sitagliptin in patients undergoing allogeneic HSCT.
- Determine the cumulative incidence of grades II-IV acute GVHD by day +100.
- To investigate the cumulative incidence of grades III-IV acute GVHD.
- To investigate the engraftment kinetics of absolute neutrophil count and platelets.
- To evaluate the incidence of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and other infections occurring during the 100 days post-transplant.
- To study non-relapse mortality (NRM) at day +100, and 1 year post-transplant.
- Determine the overall survival at 1 year post-transplant.
- Determine the incidence of chronic GVHD.
- Determine the cumulative incidence of relapse of the primary hematological malignancy.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Prospective, Multi-center, Open-label, Randomized, Controlled clinical trial of Sitagliptin for the prevention and safety of aGVHD after Alternative Donor hematopoietic stem cell transplantation.
190 adult patients with hematologic malignancies receiving haploid or unrelated donor sourced HSCT are planned to be enrolled competitively in this study from 5 clinical centers in China. These patients will be randomly assigned to two groups of 95 patients each, which one is experimental group and the other is control group. 95 patients in experimental group will receive Sitagliptin combined with Standard prophylaxis for GVHD. 95 patients in the control group will receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
Control group uses antithymocyte immunoglobulin (ATG)+cyclosporin A (CSA)+MMF+MTX for GVHD prophylaxis with the details as follows: CSA 3mg/kg continuous i.v. drip, start before Day -7, change to p.o. when gastrointestinal function recovers with a dose of 5mg/kg as two divided doses, maintaining CSA within 150-250ng/ml(If CsA cannot be tolerated, tacrolimus may be used as an alternative.); MTX 15mg/m2,Day +1, 10mg/m2,Days +3, +6, and +11; MMF 0.5g bid, starting from Day -7 to day +30 for one month; ATG 2.5mg/kg/d, Day -4 to Day -1.
Experimental group will take Sitagliptin orally from d-1 to d+14 in addition to Standard Prophylaxis Regimen.
With regard to the content of dose reduction of CSA (including time and reduction rate), it is recommended for patients with hematologic malignancies in standard risk group to start to reduce dose after 3-6 months in the absence of GVHD and reoccurrence. The specific reduction rate can be determined at each site; the patients with GVHD will be managed by routine practice in this site.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Suning Chen, Professor
- Phone Number: 8613814881746
- Email: chensuning@sina.com
Study Contact Backup
- Name: Man Qiao
- Phone Number: 8613706208979
- Email: qman_1@163.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient age ≥ 18 to ≤ 60 years
- Eastern Cooperative Oncology Group (ECOG)score 0-2 points / Karnofsky score ≧80
- To receive allogeneic hematopoietic stem cell transplantation from related haploid or unrelated donor
- The pretreatment of modified Bu/Cy+ATG scheme was planned.
- Patients with malignant hematological diseases indicated by transplantation and in complete remission (CR) state.
- Expected survival ≥ 3 months
- Signed written informed consent (Patient must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent)
- Agree to use effective contraception
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplant
- Allergy/intolerance to Sitagliptin
- There are contraindications for Sitagliptin use.
- Moderate or severe renal insufficiency
- Patients with diabetes mellitus requiring insulin secretagogues and/or insulin
- Human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection
- Active infection that is difficult to control
- Vital organ function cannot tolerate transplantation
- Other malignant tumors outside the blood system, except the following diseases: malignant tumors that have been cured for 3 years without active lesions; Adequate treatment of non-melanoma skin cancer without active foci of malignant amygdala and carcinoma in situ
- There is evidence that may interfere with the study or make patients at risk of serious complications or medical conditions, including but not limited to serious cardiovascular diseases (such as New York heart association class III or IV heart disease over the past six months of myocardial infarction, unstable type of cardiac arrhythmias) or unstable angina and/or severe lung disease (e.g. History of severe obstructive pulmonary disease and symptomatic bronchospasm)
- Pregnant or lactating women
- Any life-threatening medical condition or organ system dysfunction considered by the investigator may endanger the patient's safety by interfering with the absorption or metabolism of sitagliptin or putting study results at unnecessary risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sitagliptin Group
95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will receive Sitagliptin combined with Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
|
Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
Other Names:
|
Active Comparator: Standard Group
95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will only receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT
|
Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development Grade II-IV Acute GVHD by Day +100 Following Transplantation
Time Frame: up to 100 days
|
Percent of patients and the 95% Confidence interval who have Grade II-IV Acute GVHD by 100 days following transplantation.
Only patients who were on the study for at least 100 days post transplantation were included in the analysis.
|
up to 100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development Grade II-IV Acute GVHD at Day +100
Time Frame: 100 days from transplant
|
Fine-Gray and Cause-specific COX methods will be used to conduct a competing risk analysis.
Time until grade II-IV acute GVHD will be calculated from transplant through grade II-IV acute GVHD or death from GVHD.
Patients who relapsed or died from causes other than GVHD will be considered a competing risk population and calculated from time of transplant until relapse or death.
Otherwise, patients will be censored and calculated from transplant until the last known alive date.
The cumulative incidence percentage of grade II-IV acute GVHD at day +100 was calculated along with a 95% confidence interval.
|
100 days from transplant
|
Percentage of Patients With Grade III-IV Acute GVHD at Day +100
Time Frame: 100 days from transplant
|
Fine-Gray and Cause-specific COX methods will be used to conduct a competing risk analysis.
Time until grade III-IV acute GVHD will be calculated from transplant until grade III-IV acute GVHD or death from GVHD.
Patients who relapsed or died from causes other than GVHD will be considered a competing risk and calculated from time of transplant until relapse or death.
Otherwise, patients will be censored and calculated from transplant until the last known alive date.
The cumulative incidence percentage of grade II-IV acute GVHD at day +100 was calculated along with a 95% confidence interval.
|
100 days from transplant
|
Cumulative incidence of early transplant-related death (TRM) within 100 days after transplantation
Time Frame: 100 days from transplant
|
Percent of patients and the 95% Confidence interval who died within 100 days after transplantation.
|
100 days from transplant
|
Median Time to Engraftment of Neutrophils
Time Frame: up to 1 month
|
Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method.
The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l.
Patients who did not have neutrophil engraftment before death will be censored at the date of death.
The median and 95% confidence intervals were calculated.
|
up to 1 month
|
Median Time to Engraftment of Platelets
Time Frame: up to 4 months
|
Time to platelet engraftment will be analyzed by the Kaplan-Meier method.
The time to engraftment of platelets is defined as the time from day 0 to the first of seven consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l.
The CBCs obtained should be at least seven days after the most recent platelet transfusion.
The median and 95% confidence intervals were calculated.
|
up to 4 months
|
Number of Unique Patients With Infections by Day +100
Time Frame: 100 days from transplant
|
Number of unique patients who had each type of infection (i.e., viral, bacterial, fungal, etc.) during the 100 days post transplant.
A patient could have more than one type of infection.
|
100 days from transplant
|
Percentage of Patients With Non-relapse Mortality (NRM) at +1 Year
Time Frame: 1 year from transplant
|
Kaplan-Meier methods will be used to conduct a competing risk analysis.
Time until non-relapse death will be calculated from transplant until death.
Patients who died from relapse will be considered a competing risk and calculated from time of transplant until death.
Otherwise, patients will be censored and calculated from transplant until the last known alive date.
The cumulative incidence percentage of non-relapse mortality at day +365 was calculated along with a 95% confidence interval.
|
1 year from transplant
|
Percentage of Patients Surviving at +1 Year
Time Frame: 1 year from transplant
|
Duration of time from the start of treatment to time of death due to any causes.
Patients who do not die will be censored on their last known alive date.
Kaplan-Meier methods will be used and the median and 95% confidence intervals will be calculated.
The cumulative incidence percentage of survival at day +365 was calculated along with a 95% confidence interval.
|
1 year from transplant
|
Percentage of Patients Diagnosed With Chronic GVHD at 1 Year
Time Frame: 1 year from transplant
|
Patients surviving at least 100 days will be evaluable for chronic GVHD.
The cumulative incidence of chronic GVHD (total, and mild, moderate, severe) will be described using deaths from causes other than chronic GVHD considered as a competing risk.
Kaplan-Meier methods will be used to conduct a competing risk analysis.
Time until chronic GVHD will be calculated from transplant until chronic GVHD or death from GVHD.
Patients who relapsed or died from causes other than GVHD will be considered a competing risk and calculated from time of transplant until relapse or death.
Otherwise, patients will be censored and calculated from transplant until the last known alive date.
The cumulative incidence percentage at 1 year will calculated along with a 95% confidence interval.
|
1 year from transplant
|
Percentage of Patients With Relapse of the Primary Hematological Malignancy at 1 Year
Time Frame: 1 year from transplant
|
Kaplan-Meier methods will be used to conduct a competing risk analysis.
Time until relapse will be calculated from transplant until relapse or death from relapse.
Patients who died from causes other than relapse will be considered a competing risk and calculated from time of transplant until death.
Otherwise, patients will be censored and calculated from transplant until the last known alive date.
The cumulative incidence percentage of relapse at day +365 was calculated along with a 95% confidence interval.
|
1 year from transplant
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Suning Chen, professor, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Graft vs Host Disease
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Dermatologic Agents
- Antifungal Agents
- Reproductive Control Agents
- Incretins
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dipeptidyl-Peptidase IV Inhibitors
- Calcineurin Inhibitors
- Methotrexate
- Sitagliptin Phosphate
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- SZ-GVHD 06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allogeneic Hematopoietic Stem Cell Transplantation
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)TerminatedALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONUnited States
-
Central Hospital, Nancy, FranceRecruitingAllogeneic Hematopoietic Stem Cell TransplantationFrance
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAllogeneic Hematopoietic Stem Cell TransplantationUnited States
-
Cairo UniversityCompletedAllogeneic Hematopoietic Stem Cell TransplantationEgypt
-
Universitätsklinikum Hamburg-EppendorfStaburo GmbH; Deutsche José Carreras Leukämie-StiftungUnknownAllogeneic Hematopoietic Stem Cell TransplantationGermany
-
Fujian Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell TransplantationChina
-
Shandong Provincial HospitalUnknownAllogeneic Hematopoietic Stem Cell Transplantation | EltrombopagChina
-
Ohio State University Comprehensive Cancer CenterRecruitingAllogeneic Hematopoietic Stem Cell Transplantation RecipientUnited States
Clinical Trials on Sitagliptin + Standard Prophylaxis
-
David J. GagnonNational Institute of General Medical Sciences (NIGMS); University of New England and other collaboratorsRecruitingPneumonia | Out-Of-Hospital Cardiac ArrestUnited States
-
University of PennsylvaniaMedical University of South Carolina; NYU Langone Health; National Institute... and other collaboratorsTerminatedHead and Neck Cancer | Oral MucositisUnited States
-
Balgrist University HospitalRecruitingMicrobial Colonization | Surgical Site Infection | Antibiotic Resistant InfectionSwitzerland
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Germans Trias i Pujol Hospital; Institut Catala de Salut; Department of Health... and other collaboratorsCompleted
-
University of MalayaUnknownOrthodontic Appliance Complication
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedGraft Versus Host Disease | Ophthalmologic ComplicationsUnited States
-
Institut Pasteur du CambodgeSanofi Pasteur, a Sanofi CompanyCompletedRabies Post-exposure ProphylaxisCambodia
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownLung Transplant; Complications
-
Margaret RagniWithdrawn
-
Pavan Reddy, MDCompletedGraft vs Host Disease | Hematologic MalignanciesUnited States